Trastuzumab Deruxtecan in Low or Ultralow HER2 Metastatic Breast Cancer
- PMID: 39970412
- DOI: 10.1056/NEJMc2416654
Trastuzumab Deruxtecan in Low or Ultralow HER2 Metastatic Breast Cancer
Comment on
-
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer.N Engl J Med. 2024 Dec 5;391(22):2110-2122. doi: 10.1056/NEJMoa2407086. Epub 2024 Sep 15. N Engl J Med. 2024. PMID: 39282896 Clinical Trial.
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous